Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trialPaul Kim, Paul M. Garofolo, J. Kime et al.|The Lancet Infectious Diseases|2024Cited by 83
High-throughput methods leveraging robotics and computer vision for the development of therapeutic phage cocktailsTaylor J. R. Penke, Paul M. Garofolo, A. T. Hammack et al.|Nature Communications|2026Cited by 1